Review



ngf neutralizing antiserum  (Cedarlane)


Bioz Verified Symbol Cedarlane is a verified supplier
Bioz Manufacturer Symbol Cedarlane manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 85
      Buy from Supplier

    Structured Review

    Cedarlane ngf neutralizing antiserum
    Ngf Neutralizing Antiserum, supplied by Cedarlane, used in various techniques. Bioz Stars score: 85/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ngf-neutralizing+antiserum/Anti-Mouse+Serum%2C+Antiserum%2C+(Polyclonal)+(rabbit+serum)/pmc04250393-224-24-28
    Average 85 stars, based on 5 article reviews
    ngf neutralizing antiserum - by Bioz Stars, 2026-10
    85/100 stars

    Images

    Related Articles

    other:

    Article Title: Prolyl hydroxylase inhibitors delay neuronal cell death caused by trophic factor deprivation.
    Article Snippet: Nerve growth factor was purchased from Harlan Bioproducts for Science (Madison, WI, USA) and NGF-neutralizing antiserum was from Cedarlane Laboratories Limited (Burlington, Ontario, Canada).



    Similar Products

    ngf neutralizing antiserum  (Cedarlane)
    85
    Cedarlane ngf neutralizing antiserum
    Ngf Neutralizing Antiserum, supplied by Cedarlane, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ngf-neutralizing+antiserum/Anti-Mouse+Serum%2C+Antiserum%2C+(Polyclonal)+(rabbit+serum)/pmc04250393-224-24-28
    Average 85 stars, based on 1 article reviews
    ngf neutralizing antiserum - by Bioz Stars, 2026-10
    85/100 stars
    		  Buy from Supplier
    a neutralizing antiserum against ngf receptor trka  (Millipore)
    90
    Millipore a neutralizing antiserum against ngf receptor trka
    Possible inflammatory mediators involved in lipopolysaccharide (LPS) -induced calcitonin gene-related peptide (CGRP) release from RAW macrophages. LPS (1 μg/ml) significantly increased CGRP release from RAW macrophages (a, b, *P < 0·001). (a) Co-treatment of LPS with 1·5 and 5 μg/ml nerve growth factor <t>(NGF)</t> receptor Fc chimera (sequestering NGF), 1 and 10 ng/ml interleukin-6 (IL-6) antiserum or 1 and 10 ng/ml IL-1β antiserum significantly suppressed LPS-induced CGRP release. Higher concentrations of NGF receptor Fc chimera, IL-6 and IL-1β further suppressed CGRP release to lower levels than vehicle. * indicates P < 0·05 or P < 0·001, antisera + LPS versus vehicle. + indicates P < 0·001, antisera + LPS versus LPS. (b) Co-treatment of LPS (L) with receptor-activity-modifying protein 1 (RAMP1) antiserum (1 and 10 ng/ml) or tyrosine receptor kinase A <t>(trkA)</t> receptor antiserum (1 μg/ml) significantly enhanced LPS-induced CGRP release compared with LPS treatment (+P < 0·001). RAMP1 and trkA antisera by themselves had no effect. Mean ± SEM, n = 3.
    A Neutralizing Antiserum Against Ngf Receptor Trka, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ngf-neutralizing+antiserum/a+neutralizing+antiserum+against+ngf+receptor+trka/pmc02913219-59-2-10
    Average 90 stars, based on 1 article reviews
    a neutralizing antiserum against ngf receptor trka - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    ngf neutralizing antiserum  (Millipore)
    90
    Millipore ngf neutralizing antiserum
    Possible inflammatory mediators involved in lipopolysaccharide (LPS) -induced calcitonin gene-related peptide (CGRP) release from RAW macrophages. LPS (1 μg/ml) significantly increased CGRP release from RAW macrophages (a, b, *P < 0·001). (a) Co-treatment of LPS with 1·5 and 5 μg/ml nerve growth factor <t>(NGF)</t> receptor Fc chimera (sequestering NGF), 1 and 10 ng/ml interleukin-6 (IL-6) antiserum or 1 and 10 ng/ml IL-1β antiserum significantly suppressed LPS-induced CGRP release. Higher concentrations of NGF receptor Fc chimera, IL-6 and IL-1β further suppressed CGRP release to lower levels than vehicle. * indicates P < 0·05 or P < 0·001, antisera + LPS versus vehicle. + indicates P < 0·001, antisera + LPS versus LPS. (b) Co-treatment of LPS (L) with receptor-activity-modifying protein 1 (RAMP1) antiserum (1 and 10 ng/ml) or tyrosine receptor kinase A <t>(trkA)</t> receptor antiserum (1 μg/ml) significantly enhanced LPS-induced CGRP release compared with LPS treatment (+P < 0·001). RAMP1 and trkA antisera by themselves had no effect. Mean ± SEM, n = 3.
    Ngf Neutralizing Antiserum, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ngf-neutralizing+antiserum/ngf+antiserum/pmc02843224-36-36-43
    Average 90 stars, based on 1 article reviews
    ngf neutralizing antiserum - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    ngf-neutralizing antiserum  (Millipore)
    90
    Millipore ngf-neutralizing antiserum
    Possible inflammatory mediators involved in lipopolysaccharide (LPS) -induced calcitonin gene-related peptide (CGRP) release from RAW macrophages. LPS (1 μg/ml) significantly increased CGRP release from RAW macrophages (a, b, *P < 0·001). (a) Co-treatment of LPS with 1·5 and 5 μg/ml nerve growth factor <t>(NGF)</t> receptor Fc chimera (sequestering NGF), 1 and 10 ng/ml interleukin-6 (IL-6) antiserum or 1 and 10 ng/ml IL-1β antiserum significantly suppressed LPS-induced CGRP release. Higher concentrations of NGF receptor Fc chimera, IL-6 and IL-1β further suppressed CGRP release to lower levels than vehicle. * indicates P < 0·05 or P < 0·001, antisera + LPS versus vehicle. + indicates P < 0·001, antisera + LPS versus LPS. (b) Co-treatment of LPS (L) with receptor-activity-modifying protein 1 (RAMP1) antiserum (1 and 10 ng/ml) or tyrosine receptor kinase A <t>(trkA)</t> receptor antiserum (1 μg/ml) significantly enhanced LPS-induced CGRP release compared with LPS treatment (+P < 0·001). RAMP1 and trkA antisera by themselves had no effect. Mean ± SEM, n = 3.
    Ngf Neutralizing Antiserum, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ngf-neutralizing+antiserum/ngf+antiserum/pmc02494812-68-2-6
    Average 90 stars, based on 1 article reviews
    ngf-neutralizing antiserum - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    ngf-neutralizing antiserum  (Cedarlane)
    90
    Cedarlane ngf-neutralizing antiserum
    Possible inflammatory mediators involved in lipopolysaccharide (LPS) -induced calcitonin gene-related peptide (CGRP) release from RAW macrophages. LPS (1 μg/ml) significantly increased CGRP release from RAW macrophages (a, b, *P < 0·001). (a) Co-treatment of LPS with 1·5 and 5 μg/ml nerve growth factor <t>(NGF)</t> receptor Fc chimera (sequestering NGF), 1 and 10 ng/ml interleukin-6 (IL-6) antiserum or 1 and 10 ng/ml IL-1β antiserum significantly suppressed LPS-induced CGRP release. Higher concentrations of NGF receptor Fc chimera, IL-6 and IL-1β further suppressed CGRP release to lower levels than vehicle. * indicates P < 0·05 or P < 0·001, antisera + LPS versus vehicle. + indicates P < 0·001, antisera + LPS versus LPS. (b) Co-treatment of LPS (L) with receptor-activity-modifying protein 1 (RAMP1) antiserum (1 and 10 ng/ml) or tyrosine receptor kinase A <t>(trkA)</t> receptor antiserum (1 μg/ml) significantly enhanced LPS-induced CGRP release compared with LPS treatment (+P < 0·001). RAMP1 and trkA antisera by themselves had no effect. Mean ± SEM, n = 3.
    Ngf Neutralizing Antiserum, supplied by Cedarlane, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ngf-neutralizing+antiserum/ngf+neutralizing+antiserum/pm17760870-45-15-18
    Average 90 stars, based on 1 article reviews
    ngf-neutralizing antiserum - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    neutralizing anti-ngf antiserum  (Harlan Laboratories)
    90
    Harlan Laboratories neutralizing anti-ngf antiserum
    Possible inflammatory mediators involved in lipopolysaccharide (LPS) -induced calcitonin gene-related peptide (CGRP) release from RAW macrophages. LPS (1 μg/ml) significantly increased CGRP release from RAW macrophages (a, b, *P < 0·001). (a) Co-treatment of LPS with 1·5 and 5 μg/ml nerve growth factor <t>(NGF)</t> receptor Fc chimera (sequestering NGF), 1 and 10 ng/ml interleukin-6 (IL-6) antiserum or 1 and 10 ng/ml IL-1β antiserum significantly suppressed LPS-induced CGRP release. Higher concentrations of NGF receptor Fc chimera, IL-6 and IL-1β further suppressed CGRP release to lower levels than vehicle. * indicates P < 0·05 or P < 0·001, antisera + LPS versus vehicle. + indicates P < 0·001, antisera + LPS versus LPS. (b) Co-treatment of LPS (L) with receptor-activity-modifying protein 1 (RAMP1) antiserum (1 and 10 ng/ml) or tyrosine receptor kinase A <t>(trkA)</t> receptor antiserum (1 μg/ml) significantly enhanced LPS-induced CGRP release compared with LPS treatment (+P < 0·001). RAMP1 and trkA antisera by themselves had no effect. Mean ± SEM, n = 3.
    Neutralizing Anti Ngf Antiserum, supplied by Harlan Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ngf-neutralizing+antiserum/ngf+neutralizing+antibody/pm10954722-52-20-22
    Average 90 stars, based on 1 article reviews
    neutralizing anti-ngf antiserum - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Possible inflammatory mediators involved in lipopolysaccharide (LPS) -induced calcitonin gene-related peptide (CGRP) release from RAW macrophages. LPS (1 μg/ml) significantly increased CGRP release from RAW macrophages (a, b, *P < 0·001). (a) Co-treatment of LPS with 1·5 and 5 μg/ml nerve growth factor (NGF) receptor Fc chimera (sequestering NGF), 1 and 10 ng/ml interleukin-6 (IL-6) antiserum or 1 and 10 ng/ml IL-1β antiserum significantly suppressed LPS-induced CGRP release. Higher concentrations of NGF receptor Fc chimera, IL-6 and IL-1β further suppressed CGRP release to lower levels than vehicle. * indicates P < 0·05 or P < 0·001, antisera + LPS versus vehicle. + indicates P < 0·001, antisera + LPS versus LPS. (b) Co-treatment of LPS (L) with receptor-activity-modifying protein 1 (RAMP1) antiserum (1 and 10 ng/ml) or tyrosine receptor kinase A (trkA) receptor antiserum (1 μg/ml) significantly enhanced LPS-induced CGRP release compared with LPS treatment (+P < 0·001). RAMP1 and trkA antisera by themselves had no effect. Mean ± SEM, n = 3.

    Journal: Immunology

    Article Title: Lipopolysaccharide induces calcitonin gene-related peptide in the RAW264.7 macrophage cell line

    doi: 10.1111/j.1365-2567.2009.03239.x

    Figure Lengend Snippet: Possible inflammatory mediators involved in lipopolysaccharide (LPS) -induced calcitonin gene-related peptide (CGRP) release from RAW macrophages. LPS (1 μg/ml) significantly increased CGRP release from RAW macrophages (a, b, *P < 0·001). (a) Co-treatment of LPS with 1·5 and 5 μg/ml nerve growth factor (NGF) receptor Fc chimera (sequestering NGF), 1 and 10 ng/ml interleukin-6 (IL-6) antiserum or 1 and 10 ng/ml IL-1β antiserum significantly suppressed LPS-induced CGRP release. Higher concentrations of NGF receptor Fc chimera, IL-6 and IL-1β further suppressed CGRP release to lower levels than vehicle. * indicates P < 0·05 or P < 0·001, antisera + LPS versus vehicle. + indicates P < 0·001, antisera + LPS versus LPS. (b) Co-treatment of LPS (L) with receptor-activity-modifying protein 1 (RAMP1) antiserum (1 and 10 ng/ml) or tyrosine receptor kinase A (trkA) receptor antiserum (1 μg/ml) significantly enhanced LPS-induced CGRP release compared with LPS treatment (+P < 0·001). RAMP1 and trkA antisera by themselves had no effect. Mean ± SEM, n = 3.

    Article Snippet: A neutralizing antiserum against NGF receptor trkA was obtained from Chemicon Inc. (Temecula, CA).

    Techniques: Activity Assay